Denali Therapeutics IncNASDAQ:DNLI
- LAST PRICE24.1000
- TODAY'S CHANGE (%)0.0100 (0.0415%)
- Bid / Lots19.0000/ 1
- Ask / Lots25.9600/ 2
- Open / Previous Close24.6700 / 24.0900
- Day Range
- 52 Week Range
- Volume543,073
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | DNLI |
|---|---|---|
| 09:32 ET | 9679 | 24.56 |
| 09:34 ET | 1100 | 24.37 |
| 09:36 ET | 100 | 24.43 |
| 09:38 ET | 1064 | 24.48 |
| 09:39 ET | 2670 | 24.27 |
| 09:41 ET | 100 | 24.385 |
| 09:43 ET | 1904 | 24.49 |
| 09:45 ET | 800 | 24.53 |
| 09:50 ET | 2500 | 24.6 |
| 09:52 ET | 3100 | 24.69 |
| 09:54 ET | 1327 | 24.82 |
| 09:56 ET | 300 | 24.88 |
| 09:57 ET | 1225 | 24.7 |
| 09:59 ET | 1483 | 24.58 |
| 10:01 ET | 1550 | 24.85 |
| 10:03 ET | 2176 | 24.75 |
| 10:06 ET | 1800 | 24.75 |
| 10:08 ET | 873 | 24.66 |
| 10:10 ET | 700 | 24.55 |
| 10:12 ET | 500 | 24.61 |
| 10:14 ET | 600 | 24.56 |
| 10:15 ET | 100 | 24.495 |
| 10:17 ET | 327 | 24.53 |
| 10:19 ET | 1100 | 24.39 |
| 10:21 ET | 200 | 24.34 |
| 10:24 ET | 500 | 24.4 |
| 10:26 ET | 200 | 24.41 |
| 10:28 ET | 100 | 24.4 |
| 10:30 ET | 998 | 24.35 |
| 10:32 ET | 1648 | 24.21 |
| 10:33 ET | 1581 | 24.25 |
| 10:35 ET | 900 | 24.31 |
| 10:37 ET | 3011 | 24.42 |
| 10:39 ET | 2971 | 24.55 |
| 10:42 ET | 1212 | 24.515 |
| 10:44 ET | 387 | 24.5 |
| 10:46 ET | 400 | 24.49 |
| 10:48 ET | 1222 | 24.395 |
| 10:50 ET | 437 | 24.35 |
| 10:53 ET | 100 | 24.205 |
| 10:55 ET | 9536 | 24.23 |
| 10:57 ET | 200 | 24.16 |
| 11:00 ET | 300 | 24.16 |
| 11:02 ET | 700 | 24.09 |
| 11:04 ET | 400 | 24.115 |
| 11:06 ET | 300 | 24.145 |
| 11:08 ET | 496 | 24.1 |
| 11:09 ET | 842 | 24.165 |
| 11:11 ET | 400 | 24.155 |
| 11:13 ET | 200 | 24.11 |
| 11:18 ET | 327 | 24.04 |
| 11:20 ET | 200 | 24.0401 |
| 11:22 ET | 400 | 24.04 |
| 11:24 ET | 954 | 24.06 |
| 11:26 ET | 100 | 24.105 |
| 11:27 ET | 357 | 24.06 |
| 11:29 ET | 200 | 24.11 |
| 11:31 ET | 1686 | 24.06 |
| 11:33 ET | 100 | 24.03 |
| 11:36 ET | 400 | 23.98 |
| 11:38 ET | 1700 | 24.11 |
| 11:40 ET | 427 | 24.17 |
| 11:42 ET | 300 | 24.14 |
| 11:44 ET | 427 | 24.155 |
| 11:45 ET | 1340 | 24.11 |
| 11:47 ET | 300 | 24.12 |
| 11:51 ET | 227 | 24.16 |
| 11:54 ET | 752 | 24.14 |
| 11:56 ET | 250 | 24.1137 |
| 11:58 ET | 3409 | 24.05 |
| 12:00 ET | 600 | 24.105 |
| 12:02 ET | 500 | 24.1 |
| 12:03 ET | 400 | 24.12 |
| 12:07 ET | 735 | 24.1599 |
| 12:09 ET | 1400 | 24.18 |
| 12:12 ET | 1700 | 24.09 |
| 12:14 ET | 227 | 24.05 |
| 12:16 ET | 1000 | 24.01 |
| 12:18 ET | 200 | 24.035 |
| 12:20 ET | 300 | 24.04 |
| 12:23 ET | 856 | 24.02 |
| 12:25 ET | 300 | 24.05 |
| 12:27 ET | 668 | 24.08 |
| 12:30 ET | 200 | 24.01 |
| 12:34 ET | 300 | 24.03 |
| 12:36 ET | 5975 | 24.01 |
| 12:38 ET | 1320 | 24.01 |
| 12:39 ET | 400 | 24 |
| 12:41 ET | 500 | 24.03 |
| 12:43 ET | 500 | 24.03 |
| 12:45 ET | 700 | 24.035 |
| 12:48 ET | 300 | 24.035 |
| 12:50 ET | 400 | 24 |
| 12:52 ET | 597 | 24.02 |
| 12:54 ET | 3539 | 24.03 |
| 12:56 ET | 1500 | 24 |
| 12:57 ET | 500 | 24.015 |
| 12:59 ET | 712 | 24.03 |
| 01:01 ET | 6347 | 24.07 |
| 01:03 ET | 2001 | 23.95 |
| 01:06 ET | 324 | 23.97 |
| 01:08 ET | 500 | 23.98 |
| 01:10 ET | 900 | 23.885 |
| 01:15 ET | 100 | 23.89 |
| 01:17 ET | 397 | 23.88 |
| 01:19 ET | 500 | 23.875 |
| 01:24 ET | 100 | 23.87 |
| 01:26 ET | 600 | 23.94 |
| 01:28 ET | 200 | 23.94 |
| 01:30 ET | 660 | 23.98 |
| 01:32 ET | 1200 | 23.96 |
| 01:33 ET | 800 | 23.985 |
| 01:35 ET | 2141 | 23.92 |
| 01:37 ET | 12400 | 24.05 |
| 01:39 ET | 1904 | 24.14 |
| 01:42 ET | 1143 | 24.16 |
| 01:46 ET | 1300 | 24.23 |
| 01:48 ET | 200 | 24.31 |
| 01:50 ET | 1100 | 24.2 |
| 01:51 ET | 300 | 24.17 |
| 01:53 ET | 100 | 24.175 |
| 01:55 ET | 554 | 24.2037 |
| 01:57 ET | 400 | 24.19 |
| 02:00 ET | 200 | 24.17 |
| 02:04 ET | 896 | 24.24 |
| 02:06 ET | 400 | 24.21 |
| 02:08 ET | 499 | 24.16 |
| 02:09 ET | 300 | 24.2 |
| 02:11 ET | 300 | 24.21 |
| 02:13 ET | 400 | 24.215 |
| 02:15 ET | 600 | 24.17 |
| 02:18 ET | 2427 | 24.19 |
| 02:20 ET | 307 | 24.16 |
| 02:22 ET | 900 | 24.115 |
| 02:26 ET | 900 | 24.15 |
| 02:27 ET | 200 | 24.16 |
| 02:29 ET | 114 | 24.16 |
| 02:31 ET | 284 | 24.14 |
| 02:33 ET | 500 | 24.15 |
| 02:36 ET | 425 | 24.14 |
| 02:38 ET | 400 | 24.16 |
| 02:40 ET | 300 | 24.155 |
| 02:42 ET | 585 | 24.12 |
| 02:44 ET | 521 | 24.13 |
| 02:45 ET | 200 | 24.11 |
| 02:47 ET | 300 | 24.115 |
| 02:49 ET | 600 | 24.13 |
| 02:51 ET | 1443 | 24.15 |
| 02:54 ET | 1580 | 24.16 |
| 02:56 ET | 600 | 24.14 |
| 02:58 ET | 500 | 24.14 |
| 03:00 ET | 300 | 24.11 |
| 03:02 ET | 1900 | 24.055 |
| 03:03 ET | 100 | 24.05 |
| 03:05 ET | 4002 | 24 |
| 03:07 ET | 852 | 24.03 |
| 03:09 ET | 1227 | 24.08 |
| 03:12 ET | 200 | 24.1 |
| 03:14 ET | 3536 | 24.02 |
| 03:16 ET | 600 | 24.02 |
| 03:18 ET | 1050 | 24.0301 |
| 03:20 ET | 600 | 24.065 |
| 03:21 ET | 825 | 24.0972 |
| 03:23 ET | 300 | 24.11 |
| 03:25 ET | 1400 | 24.15 |
| 03:27 ET | 4836 | 24.17 |
| 03:30 ET | 627 | 24.22 |
| 03:32 ET | 1453 | 24.18 |
| 03:34 ET | 271 | 24.17 |
| 03:36 ET | 2785 | 24.17 |
| 03:38 ET | 700 | 24.16 |
| 03:39 ET | 700 | 24.18 |
| 03:41 ET | 1000 | 24.18 |
| 03:43 ET | 1544 | 24.19 |
| 03:45 ET | 3372 | 24.22 |
| 03:48 ET | 1199 | 24.2399 |
| 03:50 ET | 1631 | 24.21 |
| 03:52 ET | 4616 | 24.25 |
| 03:54 ET | 2764 | 24.17 |
| 03:56 ET | 6228 | 24.07 |
| 03:57 ET | 9862 | 24.13 |
| 03:59 ET | 13398 | 24.1 |
Jul 10, 2024
DJ Denali Therapeutics Is Maintained at Overweight by JP Morgan, from 12:36PM ET on Wednesday Jul 10, 2024 by Dow Jones
12:36PM ET on Wednesday Jul 10, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Denali Therapeutics Inc | 3.4B | -24.9x | --- |
Twist Bioscience Corp | 3.3B | -17.3x | --- |
MorphoSys AG | 2.8B | -5.4x | --- |
Arrowhead Pharmaceuticals Inc | 3.6B | -6.7x | --- |
Amicus Therapeutics Inc | 3.0B | -20.6x | --- |
Genmab A/S | 18.5B | 23.6x | +22.71% |
Company Information
Denali Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing a portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases and lysosomal storage disease. The Company has a portfolio of both small molecule and biotherapeutic medicines, comprising seven product candidates in clinical development across seven indications as well as preclinical therapeutic candidates. Its three late-stage development programs include tividenofusp alfa (DNL310) for mucopolysaccharidosis II (MPS II); BIIB122/DNL151 (LRRK2 inhibitor) for Parkinson’s disease; and DNL343 (eIF2B activator) for amyotrophic lateral sclerosis (ALS). SAR443820/DNL788 (RIPK1 inhibitor) is being evaluated in a Phase II study for multiple sclerosis (MS). In addition, it has a Phase I/II study of TAK-594/DNL593 for frontotemporal dementia-granulin (FTD-GRN) and a Phase I/II study of DNL126 for MPS IIIA (Sanfilippo syndrome).
Contact Information
- Headquarters
- 161 Oyster Point BlvdSOUTH SAN FRANCISCO, CA, United States 94080-1910
- Phone
- 650-866-8548
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Vicki Sato
- President, Chief Executive Officer, Director
- Ryan Watts
- Chief Financial Officer, Chief Operating Officer, Company Secretary
- Alexander Schuth
- Chief Medical Officer
- Carole Ho
- Director
- Steven Krognes
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.4B |
|---|---|
Revenue (TTM) | $295.4M |
Shares Outstanding | 142.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.38 |
EPS | $-0.97 |
Book Value | $7.45 |
P/E Ratio | -24.9x |
Price/Sales (TTM) | 11.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -65.54% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
